Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study

医学 安慰剂 银屑病 内科学 随机对照试验 银屑病面积及严重程度指数 皮肤病科 病理 替代医学
作者
Vimal H Prajapati,Marieke M.B. Seyger,Dagmar Wilsmann‐Theis,Erzsébet Szakos,Andrzej Kaszuba,Bart van Hartingsveldt,Meg Jett,Guangliang Jiang,Shu Li,Vikash Sinha,Herta Crauwels,Cynthia Marie Carver DeKlotz,Amy S. Paller
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:192 (4): 618-628 被引量:1
标识
DOI:10.1093/bjd/ljae502
摘要

Abstract Background No currently approved treatment for paediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor that targets the p19 subunit) demonstrated substantial efficacy with a favourable safety profile in treating moderate-to-severe plaque psoriasis. Objectives To evaluate the efficacy and safety of guselkumab in paediatric patients with moderate-to-severe plaque psoriasis (PROTOSTAR; NCT03451851). Methods This phase III randomized placebo-controlled study enrolled patients aged ≥ 6 to < 18 years with moderate-to-severe plaque psoriasis. In part 1 [week (W)0–W16], patients were randomized to receive guselkumab, placebo or open-label etanercept (active reference arm). At W16, part 1 patients entered a guselkumab withdrawal/retreatment period or continued/crossed over to receive guselkumab (W16–W52). Co-primary endpoints were Investigator Global Assessment (IGA) 0/1 and ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) [or U.S. Food and Drug Administration-required ≥ 90% improvement in PASI (PASI 90) co-primary endpoint] responses at W16 of part 1. Part 2 evaluated continuous open-label guselkumab treatment (W0–W52). Results Of 92 and 28 patients enrolled in parts 1 and 2, respectively, 86% and 96% continued treatment through W52. In part 1, at W16, significantly higher proportions of guselkumab-treated compared with placebo-treated patients achieved IGA 0/1 (66% vs. 16%; P < 0.001), PASI 75 (76% vs. 20%; P < 0.001) and PASI 90 (56% vs. 16%; P < 0.01). More than one-third of guselkumab-treated patients achieved clear skin [IGA 0: 39% vs. 4% placebo; 100% improvement in PASI (PASI 100): 34% vs. 0% placebo; both P < 0.01]. In part 2, at W52, 86%, 93% and 82% of guselkumab-treated patients achieved IGA 0/1, PASI 75 and PASI 90, respectively. Through W16 of part 1, 42%, 68% and 58% of guselkumab-, placebo- and etanercept-treated patients, respectively, experienced adverse events (AEs). Rates of AEs with guselkumab were similar through W52 in parts 1 and 2; common AEs included nasopharyngitis, upper respiratory tract infection and COVID-19. No serious or opportunistic infections occurred. Conclusions Guselkumab demonstrated significant and clinically meaningful responses in paediatric patients with moderate-to-severe plaque psoriasis, and all co-primary and major secondary endpoints were met. Safety outcomes for guselkumab in paediatric patients were similar to placebo and consistent with the established profile in adults, with no new safety signals identified. These findings support the use of guselkumab to treat paediatric patients with moderate-to-severe plaque psoriasis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
青雾雨的应助被水天需采纳,获得10
刚刚
刚刚
大模型的应助被科研通管家采纳,获得10
1秒前
黑米粥发布了新的文献求助200
1秒前
Orange的应助被科研通管家采纳,获得10
1秒前
隐形曼青的应助被科研通管家采纳,获得10
1秒前
所所的应助被科研通管家采纳,获得10
1秒前
桐桐的应助被科研通管家采纳,获得10
1秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
1秒前
小马甲的应助被科研通管家采纳,获得10
2秒前
在水一方的应助被科研通管家采纳,获得10
2秒前
丘比特的应助被科研通管家采纳,获得10
2秒前
大地陈发布了新的文献求助10
2秒前
小二郎的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
情怀的应助被科研通管家采纳,获得10
2秒前
情怀的应助被科研通管家采纳,获得10
2秒前
所所的应助被科研通管家采纳,获得10
3秒前
顺利白竹完成签到,获得积分10
3秒前
3秒前
科目三的应助被科研通管家采纳,获得10
3秒前
所所的应助被初初初啊采纳,获得10
3秒前
mof发布了新的文献求助10
3秒前
Ava的应助被科研通管家采纳,获得10
3秒前
汉堡包的应助被科研通管家采纳,获得10
3秒前
3秒前
大个的应助被Superman采纳,获得10
3秒前
科研通AI2S的应助被科研通管家采纳,获得10
3秒前
晚霞跌落星河的应助被renn采纳,获得30
3秒前
3秒前
Jun的应助被科研通管家采纳,获得10
3秒前
小白发布了新的文献求助10
3秒前
斯文败类的应助被科研通管家采纳,获得10
3秒前
天天快乐的应助被xujiahao采纳,获得10
4秒前
6秒前
7秒前
bkagyin的应助被顺利白竹采纳,获得10
7秒前
在水一方的应助被mof采纳,获得10
7秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184008
求助须知:如何正确求助?哪些是违规求助? 9573151
关于积分的说明 21829656
捐赠科研通 7781040
什么是DOI,文献DOI怎么找? 3434187
关于科研通互助平台的介绍 2558337
邀请新用户注册赠送积分活动 2480658